Core Viewpoint - Xinlitai (002294.SZ) has announced that its product, Aliskiren Tablets, has been included in the regular catalog of medical insurance under Category B management, reflecting the company's commitment to enhancing drug accessibility and meeting unmet clinical needs in the cardiovascular chronic disease sector [1] Group 1: Product Inclusion in Medical Insurance - Aliskiren Tablets have been included in the medical insurance catalog under Category B management [1] - Other products such as Rolitin (Aliskiren Amlodipine Tablets) and Xinlitin (Benzyl Acid Faglitin Tablets) have previously been negotiated for inclusion in the medical insurance catalog and are still under valid agreements [1] Group 2: Focus on Chronic Disease Management - The company is focusing on the cardiovascular chronic disease field, particularly on Cardio-Renal Metabolic Syndrome (CKM) [1] - A differentiated product portfolio has been established to address various pathogenesis and patient classification characteristics in hypertension, covering the entire treatment needs from primary hypertension without complications to diseases with cardio-renal target organ damage [1] Group 3: Innovation and Market Strategy - Six new chronic disease drugs have been included in the medical insurance catalog through negotiations, demonstrating national support for innovative drugs with high clinical value [1] - The company aims to leverage policy opportunities to actively promote the inclusion of negotiated drugs in hospitals and market coverage, continuously enhancing drug accessibility based on clinical value [1]

Core Viewpoint - The company, Sinopharm, has successfully negotiated the inclusion of its drugs in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List for 2025, which is expected to enhance market access and sales potential for these products [1] Group 1: Drug Inclusion in Insurance List - The drugs Xinchaotuo (Sacubitril/Valsartan) and Fuli'an (Aliskiren and Indapamide Sustained-release Tablets) have been newly included in the Class B category of the insurance list [1] - The drug Ennaruo (Entresto) has successfully renewed its contract to remain in the insurance list [1] - The drug Xinlitai (Aliskiren Tablets) has been adjusted to regular management under the insurance directory [1] Group 2: Previous Negotiations - The drugs Fuli'an (Aliskiren and Indapamide Sustained-release Tablets) and Xinliting (Bempedoic Acid Tablets) were previously included in the insurance list through negotiations and are still under valid agreements, classified under Class B [1]

Core Insights - The Shenzhen Innovation Drug Development Forum showcased ten innovative drug results, highlighting Shenzhen's strength in biopharmaceutical innovation and the integration of AI in drug development [3][4]. Group 1: Innovative Drug Results - AS1501, developed by Shenzhen University of Technology and a local pharmaceutical company, is the world's first TRAIL-DR5 pathway blocker for severe liver conditions, currently in clinical phase II, with no direct global competitors [3][4]. - BrAD-R13, a small molecule drug targeting Alzheimer's disease, has completed clinical phase I and is moving towards product transformation, aiming to provide effective treatment options for millions of patients [4]. - The AI-driven autonomous experimental platform by Crystal Technology has signed a collaboration order worth $59.9 billion with overseas pharmaceutical companies, marking a significant achievement in AI drug development [5]. Group 2: Collaborations and Innovations - A collaboration agreement worth $16.4 billion was established between Pruijng and Kite for the development of the first CAR-T therapy pipeline authorized for external use, indicating a new phase in China's in-situ editing therapy [5]. - Xinlitai launched a national class 1 innovative drug, Xiliting, for type 2 diabetes treatment, characterized by rapid oral absorption and high selectivity [5]. - Leiman Bio developed a low-dose cell therapy that can achieve 100% complete remission for advanced hematological tumors and systemic lupus erythematosus, significantly reducing production costs and treatment cycles [5].